에 대한 최신 뉴스 Cytokinetics (NASDAQ:CYTK) 주식

Cytokinetics

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics, Incorporated - Common Stock

Cytokinetics Inc

WIIM

CYTK

Cytokinetics shares are trading higher after Barclays initiated coverage on the stock with an Overweight rating and announced a price target of $55.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays analyst Gena Wang initiated coverage on Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with an Overweight rating and announced a price target of $5. Cytokinetics shares closed at $38.00 on Wednesday. <a href="https://www.benzinga.com/quote/CYTK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Lake Street analyst Jacob Stephan initiated coverage on ACCESS Newswire Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ACCS#AMEX">ACCS</a>) with a Buy rating and announced a price target of $15. ACCESS Newswire shares closed at $8.65 on Wednesday. <a href="https://www.benzinga.com/quote/ACCS/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying CYTK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="617" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24130035/image-154-1024x617.png" alt="" class="wp-image-887149" style="width:591px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24130035/image-154-1024x617.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24130035/image-154-300x181.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24130035/image-154-768x463.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24130035/image-154.png 1115w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44948767/top-2-consumer-stocks-that-may-implode-this-month">Top 2 Consumer Stocks That May Implode This Month</a> </li>
</ul>
Photo via Shutterstock

News

Initiation

Markets

Analyst Ratings

Trading Ideas

ACCS

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

Barclays analyst Gena Wang initiates coverage on Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Overweight rating and announces Price Target of $55.

Price Target

Barclays Initiates Coverage On Cytokinetics with Overweight Rating, Announces Price Target of $55

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $120 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target

On Friday, the Food and Drug Administration updated the U.S. Prescribing Information for Bristol Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Camzyos (mavacamten), simplifying treatment for patients and physicians by reducing the required echo monitoring for eligible patients in the maintenance phase and expanding patient eligibility <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">by reducing contraindications</a>.
Camzyos is the first and only FDA-approved cardiac myosin inhibitor for adults with symptomatic New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve functional <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44880541/u-s-food-and-drug-administration-updates-camzyos-mavacamten-label-to-reduce-echocardiography-monit" rel="noreferrer noopener">capacity and symptoms</a>.
FDA-approved updates include reduced frequency of required echo monitoring from once every 12 weeks to every 6 months for patients with left ventricular ejection fraction (LVEF) ≥55% and a Valsalva left ventricular outflow tract (LVOT) gradient &lt;30 mmHg (or Valsalva LVOT ≥30 mmHg without up-titration) who have reached the maintenance phase (at Week 12 or later).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44715789/fda-approves-bristol-myers-opdivo-plus-yervoy-combo-for-untreated-colorectal-cancer-patients" rel="noreferrer noopener">FDA Approves Bristol Myers&#8217; Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients</a>
Additionally, Camzyos is no longer contraindicated with moderate CYP2C19 and strong CYP3A4 inhibitors, which were adjusted to drug interactions.
The approved label update is supported by long-term clinical and real-world data, including analyses of results from the Camzyos Risk Evaluation and Mitigation Strategy (REMS) Program, real-world experience from three single-center studies, and ongoing clinical data reinforcing Camzyos&#8217;s safety profile over the past 3.5 years.
William Bliar analyst Matt Phipps writes the update is largely in line with that hinted by management and supported by real-world evidence, which will reduce the burden for physicians managing patients on Camzyos.
Phipps also views the update as timely ahead of the assumed approval of Cytokinetic Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) aficamten, with a PDUFA date of September 26.
The analyst says they are now waiting for details on the monitoring requirements for aficamten to determine potential areas of differentiation and how this may impact new market share in the coming years, assuming approval on September 26.
Last week, Bristol Myers Squibb announced topline data from the Phase 3 ODYSSEY-HCM trial of Camzyos&nbsp;(mavacamten) for symptomatic New York Heart Association (NYHA) class II-III non-obstructive&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44825297/why-us-pharma-giant-bristol-myers-squibb-stock-trading-lower-on-tuesday" rel="noreferrer noopener">hypertrophic cardiomyopathy (nHCM)</a>.
The trial did not meet its dual primary endpoints of changes from baseline to Week 48 compared to placebo in the Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score (KCCQ-23 CSS) and peak oxygen&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44801468/bristol-myers-squibb-provides-update-on-phase-3-odyssey-hcm-trial" rel="noreferrer noopener">consumption (pVO2)</a>.
No new safety signals were observed.
Price Action: BMY stock was down 0.7% at $48.83 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44895667/alibabas-ai-powered-cancer-detection-tool-wins-fda-breakthrough-status" target="_blank" rel="noreferrer noopener">Alibaba&#8217;s AI-Powered Cancer Detection Tool Wins FDA Breakthrough Status</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Biotech

Large Cap

Health Care

General

Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach

<h3>Gainers</h3>
<ul>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock moved upwards by 18.9% to $0.69 during Wednesday's after-market session. The company's market cap stands at $16.4 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock increased by 13.99% to $1.14. The company's market cap stands at $15.6 million. </li>
<li>Lineage Cell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#AMEX">LCTX</a>) stock rose 10.36% to $0.46. The company's market cap stands at $105.0 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock increased by 9.44% to $0.14. The market value of their outstanding shares is at $1.6 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares rose 9.38% to $0.41. The company's market cap stands at $21.3 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) stock increased by 8.33% to $3.25. The company's market cap stands at $2.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) shares decreased by 49.0% to $0.04 during Wednesday's after-market session. The market value of their outstanding shares is at $1.4 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares decreased by 23.0% to $0.19. The company's, Q4 earnings came out 3 days ago. </li>
<li>Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) stock declined by 16.99% to $32.5. The market value of their outstanding shares is at $3.8 billion. </li>
<li>Kiora Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPRX#NASDAQ">KPRX</a>) stock fell 11.35% to $2.5. The company's market cap stands at $7.5 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares decreased by 10.53% to $1.87. The company's market cap stands at $2.3 million. As per the press release, FY earnings came out 4 days ago. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) stock decreased by 9.44% to $0.64. The market value of their outstanding shares is at $21.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BSGM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

JUNS

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

LCTX

RDHL

REVB

SXTC

SYRA

TNFA

12 Health Care Stocks Moving In Wednesday's After-Market Session

Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) on Monday announced topline data from the Phase 3 ODYSSEY-HCM trial of Camzyos (mavacamten) for symptomatic New York Heart Association (NYHA) class II-III non-obstructive <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">hypertrophic cardiomyopathy (nHCM)</a>.
The trial did not meet its dual primary endpoints of changes from baseline to Week 48 compared to placebo in the Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score (KCCQ-23 CSS) and peak oxygen <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44801468/bristol-myers-squibb-provides-update-on-phase-3-odyssey-hcm-trial" rel="noreferrer noopener">consumption (pVO2)</a>.
No new safety signals were observed.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/04/44756157/eli-lilly-abbvie-bristol-myers-regeneron-and-other-pharma-companies-slide-as-donald-trump-confirms-tariffs-on-pharma-companies" rel="noreferrer noopener">Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies</a>
Bristol Myers Squibb will work with key investigators to share detailed results with the scientific community in the future.
Camzyos is the first and only cardiac myosin inhibitor approved in the U.S., indicated for adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms, and in the European Union, indicated for symptomatic (NYHA, class II-III) oHCM in adult patients.
William Blair writes that the press release specifically calls out that the results of the studies of mavacamten in oHCM and nHCM demonstrate that they are unique diseases, suggesting this was not a "near-miss" or one in which trends were observed.
While expansion into the nHCM patient population would have been a clear positive for Camzyos, analyst Matt Phipps did not include this opportunity in current estimates for Camzyos since the results of the Phase II MAVERICK-HCM study showed little benefit on the primary endpoints in the ODYSSEY-HCM trial.
The analyst says the trial's failure may be more attributable to differences in disease biology and sees minimal impact to Camzyos in oHCM.
Results from the Phase 2 MAVERICK-HCM trial of Camzyos showed minimal improvements in pVO2 and symptoms.
&#8220;While full results from the ODYSSEY-HCM trial will be needed to determine if the results read through to other drugs with the same mechanism being studied in nHCM, Cytokinetic Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) aficamten), we believe the Phase 2 MAVERICK-HCM and Phase 3 ODYSSEY-HCM trials suggest it could read through to the class,&#8221; William Blair writes.
<h2 class="wp-block-heading">Bristol Myers Squibb Stock Prediction For 2025</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Bristol-Myers Squibb have an average 1-year price target of $58.2, representing an expected upside of 15.68%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on Bristol-Myers Squibb, while No analysts have bullish ratings. The street high price target from Citigroup is $65.0, while the street low from UBS is $54.0.
Price Action: BMY stock is down 2.89% at $49.89 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44825031/skye-biosciences-obesity-candidate-shows-weight-loss-of-30-when-combined-with-eli-lillys-blockbuster-drug-in-animal-models">Skye Bioscience&#8217;s Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly&#8217;s Blockbuster Drug In Animal Models</a></li>
</ul>
Photo via Shutterstock

Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday?

B of A Securities analyst Jason Zemansky maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Neutral and lowers the price target from $62 to $54.

B of A Securities Maintains Neutral on Cytokinetics, Lowers Price Target to $54

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Tuesday.
Shares of Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) fell sharply in today's pre-market trading following <a href="https://in.benzinga.com/news/earnings/25/04/44802241/applied-digital-q3-earnings-revenue-misses-estimates-despite-strong-cloud-services-growth-shares-slide">weak quarterly revenue.</a>
Applied Digital reported third-quarter revenue of $52.9 million, missing analyst estimates of $63.42 million, according to Benzinga Pro. The digital infrastructure company reported a third-quarter adjusted loss of eight cents per share, beating analyst estimates for a loss of 11 cents per share.
Applied Digital shares dipped 10.8% to $4.79 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Emerald Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) fell 12.3% to $3.11 in today's pre-market trading.</li>
<li>Allegro MicroSystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) fell 12.3% to $19.29 in pre-market trading after ON Semiconductor withdrew its acquisition proposal.</li>
<li>Arlo Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) shares dipped 11.7% to $8.01 in pre-market trading. Arlo Technologies will hold a conference call on Thursday, May 8 to discuss the Company&#8217;s first quarter results.</li>
<li>IRSA Inversiones y Representaciones Sociedad Anónima (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRS#NYSE">IRS</a>) dipped 11.2% to $12.32 in pre-market trading after gaining around 9% on Monday.</li>
<li>Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) shares dipped 10.7% to $6.91 in pre-market trading.</li>
<li>1-800-FLOWERS.COM, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLWS#NASDAQ">FLWS</a>) shares fell 10.7% to $4.75 in pre-market trading.</li>
<li>LATAM Airlines Group S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTM#NYSE">LTM</a>) dipped 8.2% to $27.01 in pre-market trading.</li>
<li>Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) fell 7.1% to $37.00 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44787747/wall-streets-most-accurate-analysts-spotlight-on-3-consumer-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Consumer Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

ALGM

APLD

ARLO

CGEM

FLWS

Applied Digital Posts Weak Revenue, Joins Allegro MicroSystems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

JMP Securities analyst Jason Butler reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Market Outperform and maintains $78 price target.

JMP Securities Reiterates Market Outperform on Cytokinetics, Maintains $78 Price Target

Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $72 price target.

Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target

Citizens Capital Markets analyst Jason Butler reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Market Outperform and maintains $78 price target.

Citizens Capital Markets Reiterates Market Outperform on Cytokinetics, Maintains $78 Price Target

U.S. stocks were lower, with the Dow Jones index falling over 100 points on Wednesday.
Shares of Cognyte Software Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNT#NASDAQ">CGNT</a>) rose sharply during Wednesday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/CGNT">fourth-quarter financial results</a>.
Cognyte Software posted adjusted earnings of 3 cents per share, beating market estimates of 1 cent per share. The company's quarterly sales came in at $94.505 million versus expectations of $93.154 million.
Cognyte Software shares jumped 22.1% to $10.04 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) shares rose 13.7% to $10.98 after the company reported better-than-expected third-quarter sales results and raised its FY25 guidance above estimates.</li>
<li>Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) gained 13.1% to $14.26.</li>
<li>Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) shares rose 12% to $41.99.</li>
<li>Redfin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) shares surged 11.7% to $10.69.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) gained 10.1% to $57.90.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) rose 9.8% to $7.04.</li>
<li>Mr. Cooper Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) surged 9.5% to $136.97.</li>
<li>Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) gained 8.3% to $1.6250.</li>
<li>Allegiant Travel Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) rose 7.1% to $54.45. Raymond James analyst Savanthi Syth upgraded Allegiant Travel from Outperform to Strong Buy and lowered the price target from $125 to $90.</li>
<li>Studio City International Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSC#NYSE">MSC</a>) gained 7% to $3.85.</li>
<li>Arcellx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) gained 5.9% to $64.28.</li>
<li>Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) shares rose 4.6% to $64.34.</li>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) rose 3.8% to $248.24 ahead of quarterly earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44605585/how-to-earn-500-a-month-from-conagra-brands-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Conagra Brands Stock Ahead Of Q3 Earnings</a></li>
</ul>
Photo via Shutterstock

Intraday Update

ACLX

ALGT

ANGO

CGNT

CIEN

COOP

CRWV

GYRE

RDFN

SANA

Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Friday.
Shares of Scholastic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCHL#NASDAQ">SCHL</a>) rose sharply during Friday's session following upbeat <a href="https://www.benzinga.com/quote/SCHL/earnings">quarterly earnings</a>.
Scholastic reported quarterly losses of 5 cents per share which beat the analyst consensus estimate of a loss of 78 cents per share. The company reported quarterly sales of $335.400 million which missed the analyst consensus estimate of $347.680 million.
Scholastic shares jumped 12.2% to $21.09 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares jumped 30% to $58.51.</li>
<li>AleAnna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNA#NASDAQ">ANNA</a>) jumped 23.7% to $9.44.</li>
<li>Ouster, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>) gained 20.8% to $10.12 after the company reported better-than-expected quarterly financial results.</li>
<li>Northern Dynasty Minerals Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAK#NYSE">NAK</a>) shares rose 14% to $0.8021.</li>
<li>Torrid Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) jumped 9% to $6.03 following better-than-expected quarterly results.</li>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) rose 8.2% to $4.4351. Needham analyst Ryan MacDonald reiterated Agilon Health with a Hold rating.</li>
<li>Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) gained 5.5% to $45.47.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) gained 7.5% to $8.33. Goldman Sachs analyst Salveen Richter upgraded Adaptive Biotechnologies from Neutral to Buy and raised the price target from $8 to $9.</li>
<li>Precigen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) shares rose 7% to $1.9250.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/03/44414749/top-2-defensive-stocks-that-may-keep-you-up-at-night-in-march">Top 2 Defensive Stocks That May Keep You Up At Night In March</a></li>
</ul>
Photo: Shutterstock

ADPT

ANNA

CURV

OUST

PGEN

SCHL

Scholastic Posts Strong Earnings, Joins Ouster, Torrid Holdings, Adaptive Biotechnologies And Other Big Stocks Moving Higher On Friday

Cytokinetics Said Maintain Expectation For Differentiated Label & Risk Mitigation Profile For Aficamten, If Approved By FDA

High-rolling investors have positioned themselves bearish on Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CYTK often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 11 options trades for Cytokinetics. This is not a typical pattern.
The sentiment among these major traders is split, with 18% bullish and 72% bearish. Among all the options we identified, there was one put, amounting to $26,400, and 10 calls, totaling $2,209,345.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $45.0 to $60.0 for Cytokinetics over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Cytokinetics stands at 6050.25, with a total volume reaching 9,826.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Cytokinetics, situated within the strike price corridor from $45.0 to $60.0, throughout the last 30 days.
<h3>Cytokinetics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740775612_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.3</td>
<td>$8.0</td>
<td>$8.3</td>
<td>$60.00</td>
<td>$593.4K</td>
<td>10.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$6.5</td>
<td>$6.1</td>
<td>$6.1</td>
<td>$50.00</td>
<td>$301.9K</td>
<td>12.9K</td>
<td>503</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$7.5</td>
<td>$6.6</td>
<td>$6.6</td>
<td>$50.00</td>
<td>$301.6K</td>
<td>12.9K</td>
<td>1.5K</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.4</td>
<td>$8.0</td>
<td>$8.4</td>
<td>$60.00</td>
<td>$238.5K</td>
<td>10.8K</td>
<td>297</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$6.1</td>
<td>$5.8</td>
<td>$5.8</td>
<td>$50.00</td>
<td>$233.1K</td>
<td>12.9K</td>
<td>2.0K</td>
</tr>
</tbody>
</table>

<h3>About Cytokinetics</h3>
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Following our analysis of the options activities associated with Cytokinetics, we pivot to a closer look at the company's own performance.
<h3>Where Is Cytokinetics Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,337,052, the price of CYTK is down by -6.22%, reaching $44.5.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 68 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Cytokinetics</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $84.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a positive move, an analyst from Morgan Stanley has upgraded their rating to Overweight and adjusted the price target to $67. 
&#x2A; An analyst from Citigroup has revised its rating downward to Buy, adjusting the price target to $86. 
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $72. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $120. 
&#x2A; Reflecting concerns, an analyst from JMP Securities lowers its rating to Market Outperform with a new price target of $78.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cytokinetics options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Smart Money Is Betting Big In CYTK Options

Cytokinetics shares are trading lower after the company reported a Q4 Gaap EPS miss.

Press Releases

Cytokinetics to Announce Fourth Quarter Results on February 27, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Earnings

Cytokinetics Reports Fourth Quarter 2024 Financial Results  and Provides Business Update

Cytokinetics to Participate in March Investor Conferences

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Comments

Cytokinetics

뉴스

에 대한 최신 뉴스 Cytokinetics (NASDAQ:CYTK) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌